Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure

The Journal of Veterinary Medical Science

Shuichi CHIMURA¹  Junichiro TAKEUCHI²  Shuhei UCHIDA²  Tamotsu SAWADA²  Takeshi MIZUNO²  Masaaki ENDO²  Masami UECHI²  Kayoko HARADA²  Asako SHINODA²  Arane TAKAHASHI²  Takahiro MIZUKOSHI²  Masashi MIZUNO²  Yoshimi TAKUSAGAWA²  Shigeki YAMANO²  Shigeki MAETANI³  Atsushi HIRAKAWA⁴ 

[1] Chimura Animal Hospital, 20-13, Minami Karooke, Nakamatomachi, Iwakura, Aichi 482-0042, Japan;Japan Animal Specialty Medical Institute Inc., JASMINE Veterinary Cardiovascular Medical Center, 2-7-3 Nakagawa, Tsuzuki, Yokohama, Kanagawa 224-0001, Japan;Maetani Animal Hospital, 3 Jou, 1-1-7, Taihei, Kita-ku, Sapporo, Hokkaido 002-8003 Japan;Pet Clinic Halleluya, 1-30-63, Heiwa, Minami-ku, Fukuoka, Fukuoka 815-0071, Japan

关键词: angiotensin-converting enzyme inhibitor;    calcium sensitizer;    canine;    mitral regurgitation;   

DOI  :  10.1292/jvms.16-0069

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD). Records of 197 client-owned dogs from 14 veterinary hospitals were included in this study. Dogs were administered conventional treatments with or without pimobendan. Sixty-four dogs received a standard dose of pimobendan (0.20–0.48 mg/kg every 12 hr (q12hr)), 49 dogs received a low dose of pimobendan (0.05–0.19 mg/kg q12hr), and 84 dogs received conventional therapy alone. Dogs in the standard-dose and low-dose pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P<0.001). The reoccurrence rate of pulmonary edema in the standard-dose group was significantly lower than in the low-dose and conventional groups (43%, 59% and 62%, respectively; P<0.05). Combination of pimobendan with a conventional treatment regimen significantly prolonged survival time after an initial episode of pulmonary edema in dogs with CHF caused by MMVD. There was no difference in survival between dogs administered standard and low doses of pimobendan, but pimobendan did prevent the reoccurrence of pulmonary edema in a dose-dependent manner.

【 授权许可】

Unknown